Renovaro BioSciences issues shareholder letter

Renovaro issued a letter to shareholders from Chief Executive Officer David Weinstein. “It is my honor to address you as the newly appointed CEO of Renovaro… The future of multi-cancer early detection screening and recurrence testing reached an inflection point four years ago when the Nvidia-powered AI chips were introduced. RenovaroCube, Freenome, and other new entrants have the potential to set the standard because they are processing vast data sets with multiple biomarkers. Our moonshot is to achieve a test accuracy over 95% and, ultimately, to provide patients with rapid results from a simple blood draw taken when they have their physical exam. We are excited about the Company’s prospects and believe that over the next five years we will be part of the paradigm shift within the industry… Suffice it to say that both potential solutions represent billion-dollar opportunities… Our goal is to advance from science to business. To accomplish this, I brought on an entirely new Board of Directors. They have both Wall Street experience and deep knowledge of biotechnology, AI, corporate governance, and public company finance. Through the upcoming months, I will keep you informed and engaged in this journey. I am committed to solidifying our team and building the future. We are establishing proper corporate governance and transparency, which is important for all stakeholders. “